In a post hoc analysis of the ANNEXa-I trial (n=434) of factor Xa inhibitor-associated ICH, 72.1% had at least one NCCT marker and 31.8% had haematoma expansion; heterogeneous density, hypodensity and black hole sign independently predicted expansion.
Secondary analysisn = 434
Tanaka et al. Non-contrast CT Markers of Hematoma Expansion and Andexanet Response in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: An Analysis from ANNEXa-I Trial